Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis

• Main Authors: S. Todesco (Author), U. Fiocco (Author), M. Biscaro (Author), P. Ostuni (Author), A. Furlan (Author), P. Sfriso (Author), C. Botsios (Author), L. Punzi (Author)
• Format: Book
• Published: PAGEPress Publications, 2011-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: We evaluated both the efficacy and safety of anakinra in daily routine rheumatoid arthritis clinical practice. Methods:We studied 60 cases, including patients with previous anti-TNFα exposure, treated with anakinra (100 mg/daily s.c.) in combination with methotrexate (7.5-10 mg/week i.m.)...